Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$1.04 - $2.14 $62,667 - $128,949
-60,257 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$2.08 - $12.2 $49,953 - $292,995
-24,016 Reduced 28.5%
60,257 $172,000
Q4 2021

Feb 14, 2022

SELL
$11.48 - $17.69 $45,357 - $69,893
-3,951 Reduced 4.48%
84,273 $1 Million
Q3 2021

Nov 12, 2021

BUY
$14.57 - $17.72 $349,796 - $425,421
24,008 Added 37.39%
88,224 $1.37 Million
Q2 2021

Aug 16, 2021

BUY
$20.3 - $33.6 $809,482 - $1.34 Million
39,876 Added 163.83%
64,216 $1.31 Million
Q1 2021

May 17, 2021

BUY
$19.1 - $34.94 $148,789 - $272,182
7,790 Added 47.07%
24,340 $553,000
Q4 2020

Feb 16, 2021

BUY
$13.2 - $32.74 $218,460 - $541,847
16,550 New
16,550 $458,000

Others Institutions Holding ALGS

About Aligos Therapeutics, Inc.


  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $751M
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.